The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
REGENTIS BIOMATERIALS LTD. Chief Accounting Officer Arie Gordashnikov filed an initial insider ownership report on Form 3. This filing establishes his status as an executive officer of the company and provides the baseline disclosure of his position for future insider trading reports. No transactions are reported.
REGENTIS BIOMATERIALS LTD. director Efraim Cohen-Arazi has filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. The filing establishes his reporting status as a director of the company but does not show any transactions.
REGENTIS BIOMATERIALS LTD. Chief Financial Officer Gon Ori reported an initial holding of employee stock options. These options allow the purchase of 84,951 shares of common stock at an exercise price of $4.0000 per share and expire on February 23, 2037.
The option was granted on February 23, 2026 and vests over three years, with one-sixth vesting six months after the grant date and the remainder vesting quarterly, subject to continuous employment through each vesting date.
REGENTIS BIOMATERIALS LTD. director Ben-Elazar Pini reported his initial ownership position in a Form 3 filing. He holds employee stock options covering 39,295 shares of common stock at an exercise price of $0.01 per share, fully vested and expiring on January 23, 2035.
He also holds warrants to purchase 15,831 ordinary shares of common stock at an exercise price of $5.00 per share, which are currently exercisable and have a three-year term, expiring on December 5, 2028. In addition, he directly owns 128,666 ordinary shares with no par value per share. The filing reflects holdings only and does not report new purchases or sales.
REGENTIS BIOMATERIALS LTD. director Jeff Dykan filed an initial ownership report showing indirect positions held through venture funds he manages. The filing lists 270,473 ordinary shares held by SCP Vitalife Partners II L.P. and 130,465 ordinary shares held by SCP Vitalife Partners (Israel) II L.P. Dykan is the general partner of these SCVP entities and holds voting and dispositive power over their shares. In addition, the SCVP funds hold warrants that are currently exercisable for 6,122 and 2,083 ordinary shares at an exercise price of $5.00 per share, each with a three-year term expiring on December 5, 2028.
Regentis Biomaterials Ltd. files an amended Form 20-F for the year ended December 31, 2025 to correct formatting errors in two financial statement pages caused by its financial printer. The amendment does not update or change any other disclosures or reflect subsequent events.
The company reports 5,179,378 ordinary shares outstanding as of December 31, 2025 and describes itself as a regenerative medicine business focused on orthopedic cartilage repair using its Gelrin hydrogel platform. Its lead product candidate GelrinC holds a CE mark in Europe, and the filing highlights ongoing funding needs and going concern risks.
Regentis Biomaterials Ltd., an Israeli regenerative medicine company, focuses on GelrinC, a hydrogel implant designed to regenerate damaged knee cartilage. GelrinC has held a CE mark in Europe since 2017, and a pivotal clinical study is underway in the United States and Europe.
The company has a limited operating history, depends heavily on GelrinC, and reports significant losses. For 2025 it recorded a net loss of $13.6 million and an accumulated deficit of $55.8 million, with $7.4 million in cash and cash equivalents. A December 2025 IPO raised $10 million.
The financial statements include a going concern warning, and management expects operating losses to continue, requiring substantial additional funding. Key risks include clinical and regulatory uncertainty, strong competition in cartilage repair, reliance on third-party manufacturers and CROs, intellectual property challenges, exposure to Israeli geopolitical instability, and currency and macroeconomic pressures.
Regentis Biomaterials reported 2025 results and highlighted its lead cartilage repair product, GelrinC. The company has $7.4 million in cash, which it expects will fund completion of site expansion and patient enrollment for its pivotal Phase III FDA trial and support a planned 2026 European rollout.
Management described 2025 as transformational, citing a successful IPO and a strengthened balance sheet with more than $7 million in cash. GelrinC already has CE Mark approval in Europe and is positioned to be the first ready-to-use, off-the-shelf product in the U.S. for knee cartilage repair, targeting about 470,000 annual U.S. cartilage repair cases.
The company also disclosed that its independent auditor’s opinion on the 2025 financial statements includes a going concern qualification, signaling material uncertainty about its ability to continue operating without additional financing or improved performance, although no changes were made to the audited financials themselves.
Regentis Biomaterials Ltd. reported that a group of related investors led by Dr. Ehud Geller holds a significant stake in its Ordinary Shares. The Reporting Persons collectively beneficially own 1,332,867 Ordinary Shares, representing 23.2% of the class as of the measurement date.
This ownership figure includes 465,533 options exercisable into 465,533 Ordinary Shares and 92,821 warrants exercisable into 92,821 Ordinary Shares that are currently exercisable or will become exercisable within 60 days after December 31, 2025. The percentage is based on 5,179,378 Ordinary Shares outstanding as of February 20, 2026, plus the shares underlying these options and warrants.
The group, which includes several Medica III and Poalim Medica limited partnerships in Israel and the Cayman Islands, reports zero sole voting or dispositive power and shared voting and dispositive power over all 1,332,867 shares.
Regentis Biomaterials Ltd. is expanding its European clinical site network to support both its commercial plans and ongoing clinical programs for GelrinC®, its lead knee cartilage repair product. GelrinC® already has CE Mark approval in Europe and is slated for commercial launch there in 2026.
The company is adding new sites in regions including Italy and Eastern Europe to deepen relationships with leading orthopedic surgeons and centers of excellence. GelrinC® is described as an off-the-shelf, 10-minute procedure that has shown sustained pain relief and functional improvement for more than 4 years and is currently in a pivotal U.S. FDA study that has completed over 50% enrollment.